Zoetis Financial Diagnostics

ZTS -- USA Stock  

USD 119.46  0.76  0.63%

The small decline in market price for the last few months may raise some interest from investors as it closed today at a share price of 118.7 on 1 in trading volume. The company management did not add much value to Zoetis investors in October. However, diversifying your holdings with Zoetis or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 1.5983. The below-average Stock volatility is a good sign for a longer term investment options and for buy-and-hold investors. This diagnostics interface makes it easy to digest most current publicly released information about Zoetis as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Zoetis price relationship with some important fundamental indicators such as market cap and management efficiency. See also Your Current Watchlist.

Zoetis Note

About 95.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 2.75. Zoetis last dividend was issued on 2019-10-21. Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drugs - Generic classification in USA and is traded on BATS Exchange. It employs 10000 people. For more information please call Juan Alaix at 973 822-7000 or visit www.zoetis.com.

Zoetis Alerts

Zoetis generates negative expected return over the last 30 days
Zoetis has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial commitments
Over 95.0% of the company outstanding shares are owned by institutional investors
Latest headline from MacroaxisInsider: Acquisition by Alejandro Bernal of 1874 shares of Zoetis subject to Rule 16b-3

Zoetis Upcoming and Recent Events

Upcoming Quarterly Earning ReportFebruary 13, 2020
Next Earnings ReportMay 7, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndFebruary 13, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Zoetis Earning Estimates

EPSEstimate Date
Quarterly Estimate0.88February 13, 2020
Zoetis normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Zoetis SEC Filings

Financial Statements and Exhibits. Results of Operations and Financial Condition
Financial Statements and Exhibits. Regulation FD Disclosure
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Termination of a Material Definitive Agreement. Entry into a Material Definitive Agreement
Financial Statements and Exhibits. Regulation FD Disclosure
Financial Statements and Exhibits. Results of Operations and Financial Condition

Zoetis Thematic Classifications

Obamacare Repeal IdeaObamacare Repeal
Large healthcare related equities associated with Obamacare

Institutional Investors

Security TypeSharesValue
Blackrock IncCommon Shares38.7 M4.8 B
Vanguard Group IncCommon Shares37.1 M4.6 B
State Street CorpCommon Shares19.6 M2.4 B
State Farm Mutual Automobile Insurance CoCommon Shares19.1 M2.4 B
Alliancebernstein LpCommon Shares14.1 M1.8 B
Fmr LlcCommon Shares12.2 M1.5 B
Bank Of America CorpCommon Shares10.9 M1.4 B

Market Capitalization

The company currently falls under 'Large-Cap' category with total capitalization of 56.58 B.


The company has Net Profit Margin of 23.76 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 39.29 % which entails that for every 100 dollars of revenue it generated 0.39 of operating income.

Management Efficiency

Zoetis has Return on Asset of 11.71 % which means that on every $100 spent on asset it made $11.71 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 60.93 % implying that it generated $60.93 on every 100 dollars invested.

Stock Holders for Zoetis

At Risk
Nasdaq DM Ex Korea EUR NTR(0.0267) (0.60) 
NYSE(0.0055) (2.14) 
Lord Abbett Growth Leaders Fd C(0.1) (2.24) 
Lord Abbett Growth Leaders Fd C(0.16) (1.96) 
Lord Abbett Health Care Fund - Class A(0.0085) (1.68) 
Ivy Large Cap Growth Fund Class(0.06) (1.83) 
Polen Growth Fund Institutional(0.0148) (1.75) 
Nasdaq US Large Cap Growth NTR(0.0007) (1.63) 
NQ US Pharma Large Mid Cap TR 0.0067 (1.71) 
NQ US Pharma Large Mid Cap CAD 0.06 (1.50) 
NQ US Pharma Large Mid Cap AUD 0.18 (1.02) 
NQ US Pharma Large Mid Cap AUD 0.14 (1.38) 
NQ US Pharma Biotech Lg Md C 0.17 (1.18) 
NQ US Pharma Biotech Lg Md C 0.39 (1.91) 
NASDAQ N America Large Mid Cap 0.0014 (2.48) 
NASDAQ N America Large Mid Cap 0.0268 (1.25) 
NASDAQ N America Health Care Lg 0.06 (1.88) 
NASDAQ N America Health Care Lg 0.06 (1.90) 
NASDAQ N America Health Care Lg 0.05 (1.74) 
NASDAQ N America Health Care Lg 0.09 (1.76) 

Technical Drivers

As of 22 of November Zoetis maintains Market Risk Adjusted Performance of (0.13) and Mean Deviation of 1.16. Relative to Fundamental Indicators, Macroaxis technical analysis interface lets you check existing technical drivers of Zoetis as well as the relationship between them. Specifically you can use this information to find out if the organization will indeed mirror its model of past data patterns or the prices will eventually revert. We found nineteen technical drivers for Zoetis which can be compared to its rivals. Please check out Zoetis Treynor Ratio, and the relationship between Variance and Potential Upside to decide if Zoetis is priced fairly providing market reflects its latest price of 119.46 per share. Given that Zoetis has Jensen Alpha of (0.14), we strongly advise you confirm Zoetis prevalent market performance to make sure the company can sustain itself at future point.

Zoetis Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Parabolic SAR indicator is used to determine the direction of Zoetis momentum and the point in time when Zoetis has higher than normal probability directional change. View also all equity analysis or get more info about parabolic sar overlap studies indicator.

Zoetis Insider Trading Activities

Zoetis Outstanding Bonds

98978VAB9 3.25%02/01/20233.25
98978VAE3 1.15%02/01/20161.15
98978VAG8 1.875%02/01/20181.875
98978VAH6 4.7%02/01/20434.7

Zoetis Predictive Indicators

Zoetis Forecast Models


Zoetis Analyst Recommendations

Target PriceAdvice# of Analysts
Zoetis current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Zoetis Analyst Advice  

Vital Value Indicators

Zoetis Basic Pricing Drivers

Quick Ratio2.73
Fifty Two Week Low78.90
Trailing Annual Dividend Rate0.62
Revenue Growth7.00%
Payout Ratio20.46%
Shares Short Prior Month4.42M
Average Daily Volume Last 10 Day2.64M
Average Daily Volume In Three Month2.08M
Earnings Growth26.80%
Shares Percent Shares Out0.77%
Gross Margins68.68%
Earnings Quarterly Growth24.80%
Short Percent Of Float0.77%
Forward Price Earnings29.63
Float Shares475.7M
Fifty Two Week High130.20
Enterprise Value To Ebitda25.24
Fifty Day Average123.93
Two Hundred Day Average117.32
Trailing Annual Dividend Yield0.52%
Enterprise Value To Revenue9.92
See also Your Current Watchlist. Please also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Search macroaxis.com